Levodopa-carbidopa intestinal gel for advanced Parkinson's disease: Impact of LRRK2 and GBA1 mutations

Avner Thaler; Saar Anis; Penina Ponger; Tsviya Fay-Karmon; Vered Livneh; Achinoam Faust-Socher; Lior Greenbaum; Johnathan Reiner; Ariela Hilel; Hertzel Shabtai; Roy N. Alcalay; Ruth Djaldetti; Sharon Hassin-Baer; Adi Ezra; Anat Mirelman; Nir Giladi; Tanya Gurevich

doi:10.1016/j.parkreldis.2024.107115

Levodopa-carbidopa intestinal gel for advanced Parkinson's disease: Impact of LRRK2 and GBA1 mutations

Avner Thaler, Saar Anis, Penina Ponger, Tsviya Fay-Karmon, Vered Livneh, Achinoam Faust-Socher, Lior Greenbaum, Johnathan Reiner, Ariela Hilel, Hertzel Shabtai, Roy N. Alcalay, Ruth Djaldetti, Sharon Hassin-Baer, Adi Ezra, Anat Mirelman, Nir Giladi, Tanya Gurevich

Tel Aviv University

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Advanced Parkinson's disease (PD) can be treated with Levodopa-Carbidopa Intestinal Gel (LCIG). Objective: To compare descriptive data of LCIG treatment in GBA1-PD and LRRK2-PD. Methods: This multicenter retrospective study compared clinical data obtained from electronic medical records of PD patients treated with LCIG. Patients were grouped based on their genetic status. Results: Fifty-two iPD, 15 LRRK2-PD and 23 GBA1-PD were included in this study. No difference in daily dose of LCIG or levodopa equivalent daily dose were detected. GBA1-PD had significantly shorter disease duration at LCIG initiation (p = 0.01) and experienced more hallucinations (p = 0.03) compared with LRRK2-PD and iPD. LRRK2-PD and iPD had significantly longer duration of LCIG treatment compared with GBA1-PD (p < 0.01). Conclusion: Overall, LCIG treatment was well tolerated in LRRK2-PD and GBA1-PD. GBA1-PD required LCIG earlier in their course of their disease and had higher frequencies of hallucinations during treatment, attesting to a more severe disease course.

Original language	English
Article number	107115
Journal	Parkinsonism and Related Disorders
Volume	127
DOIs	https://doi.org/10.1016/j.parkreldis.2024.107115
State	Published - Oct 2024

Keywords

GBA1
Levodopa-carbidopa intestinal gel
Parkinson's disease LRRK2

All Science Journal Classification (ASJC) codes

Neurology
Geriatrics and Gerontology
Clinical Neurology

Access to Document

10.1016/j.parkreldis.2024.107115

Cite this

Thaler, A., Anis, S., Ponger, P., Fay-Karmon, T., Livneh, V., Faust-Socher, A., Greenbaum, L., Reiner, J., Hilel, A., Shabtai, H., Alcalay, R. N., Djaldetti, R., Hassin-Baer, S., Ezra, A., Mirelman, A., Giladi, N., & Gurevich, T. (2024). Levodopa-carbidopa intestinal gel for advanced Parkinson's disease: Impact of LRRK2 and GBA1 mutations. Parkinsonism and Related Disorders, 127, Article 107115. https://doi.org/10.1016/j.parkreldis.2024.107115

@article{e03d97c15e684b83914a0bfc467d023b,

title = "Levodopa-carbidopa intestinal gel for advanced Parkinson's disease: Impact of LRRK2 and GBA1 mutations",

abstract = "Background: Advanced Parkinson's disease (PD) can be treated with Levodopa-Carbidopa Intestinal Gel (LCIG). Objective: To compare descriptive data of LCIG treatment in GBA1-PD and LRRK2-PD. Methods: This multicenter retrospective study compared clinical data obtained from electronic medical records of PD patients treated with LCIG. Patients were grouped based on their genetic status. Results: Fifty-two iPD, 15 LRRK2-PD and 23 GBA1-PD were included in this study. No difference in daily dose of LCIG or levodopa equivalent daily dose were detected. GBA1-PD had significantly shorter disease duration at LCIG initiation (p = 0.01) and experienced more hallucinations (p = 0.03) compared with LRRK2-PD and iPD. LRRK2-PD and iPD had significantly longer duration of LCIG treatment compared with GBA1-PD (p < 0.01). Conclusion: Overall, LCIG treatment was well tolerated in LRRK2-PD and GBA1-PD. GBA1-PD required LCIG earlier in their course of their disease and had higher frequencies of hallucinations during treatment, attesting to a more severe disease course.",

keywords = "GBA1, Levodopa-carbidopa intestinal gel, Parkinson's disease LRRK2",

author = "Avner Thaler and Saar Anis and Penina Ponger and Tsviya Fay-Karmon and Vered Livneh and Achinoam Faust-Socher and Lior Greenbaum and Johnathan Reiner and Ariela Hilel and Hertzel Shabtai and Alcalay, {Roy N.} and Ruth Djaldetti and Sharon Hassin-Baer and Adi Ezra and Anat Mirelman and Nir Giladi and Tanya Gurevich",

note = "Publisher Copyright: {\textcopyright} 2024 Elsevier Ltd",

year = "2024",

month = oct,

doi = "10.1016/j.parkreldis.2024.107115",

language = "الإنجليزيّة",

volume = "127",

journal = "Parkinsonism and Related Disorders",

issn = "1353-8020",

publisher = "Elsevier Ltd.",

}

Thaler, A, Anis, S, Ponger, P, Fay-Karmon, T, Livneh, V, Faust-Socher, A, Greenbaum, L, Reiner, J, Hilel, A, Shabtai, H, Alcalay, RN, Djaldetti, R, Hassin-Baer, S, Ezra, A, Mirelman, A, Giladi, N & Gurevich, T 2024, 'Levodopa-carbidopa intestinal gel for advanced Parkinson's disease: Impact of LRRK2 and GBA1 mutations', Parkinsonism and Related Disorders, vol. 127, 107115. https://doi.org/10.1016/j.parkreldis.2024.107115

TY - JOUR

T1 - Levodopa-carbidopa intestinal gel for advanced Parkinson's disease

T2 - Impact of LRRK2 and GBA1 mutations

AU - Thaler, Avner

AU - Anis, Saar

AU - Ponger, Penina

AU - Fay-Karmon, Tsviya

AU - Livneh, Vered

AU - Faust-Socher, Achinoam

AU - Greenbaum, Lior

AU - Reiner, Johnathan

AU - Hilel, Ariela

AU - Shabtai, Hertzel

AU - Alcalay, Roy N.

AU - Djaldetti, Ruth

AU - Hassin-Baer, Sharon

AU - Ezra, Adi

AU - Mirelman, Anat

AU - Giladi, Nir

AU - Gurevich, Tanya

PY - 2024/10

Y1 - 2024/10

N2 - Background: Advanced Parkinson's disease (PD) can be treated with Levodopa-Carbidopa Intestinal Gel (LCIG). Objective: To compare descriptive data of LCIG treatment in GBA1-PD and LRRK2-PD. Methods: This multicenter retrospective study compared clinical data obtained from electronic medical records of PD patients treated with LCIG. Patients were grouped based on their genetic status. Results: Fifty-two iPD, 15 LRRK2-PD and 23 GBA1-PD were included in this study. No difference in daily dose of LCIG or levodopa equivalent daily dose were detected. GBA1-PD had significantly shorter disease duration at LCIG initiation (p = 0.01) and experienced more hallucinations (p = 0.03) compared with LRRK2-PD and iPD. LRRK2-PD and iPD had significantly longer duration of LCIG treatment compared with GBA1-PD (p < 0.01). Conclusion: Overall, LCIG treatment was well tolerated in LRRK2-PD and GBA1-PD. GBA1-PD required LCIG earlier in their course of their disease and had higher frequencies of hallucinations during treatment, attesting to a more severe disease course.

AB - Background: Advanced Parkinson's disease (PD) can be treated with Levodopa-Carbidopa Intestinal Gel (LCIG). Objective: To compare descriptive data of LCIG treatment in GBA1-PD and LRRK2-PD. Methods: This multicenter retrospective study compared clinical data obtained from electronic medical records of PD patients treated with LCIG. Patients were grouped based on their genetic status. Results: Fifty-two iPD, 15 LRRK2-PD and 23 GBA1-PD were included in this study. No difference in daily dose of LCIG or levodopa equivalent daily dose were detected. GBA1-PD had significantly shorter disease duration at LCIG initiation (p = 0.01) and experienced more hallucinations (p = 0.03) compared with LRRK2-PD and iPD. LRRK2-PD and iPD had significantly longer duration of LCIG treatment compared with GBA1-PD (p < 0.01). Conclusion: Overall, LCIG treatment was well tolerated in LRRK2-PD and GBA1-PD. GBA1-PD required LCIG earlier in their course of their disease and had higher frequencies of hallucinations during treatment, attesting to a more severe disease course.

KW - GBA1

KW - Levodopa-carbidopa intestinal gel

KW - Parkinson's disease LRRK2

UR - http://www.scopus.com/inward/record.url?scp=85202199686&partnerID=8YFLogxK

U2 - 10.1016/j.parkreldis.2024.107115

DO - 10.1016/j.parkreldis.2024.107115

M3 - مقالة

C2 - 39208588

SN - 1353-8020

VL - 127

JO - Parkinsonism and Related Disorders

JF - Parkinsonism and Related Disorders

M1 - 107115

ER -

Levodopa-carbidopa intestinal gel for advanced Parkinson's disease: Impact of LRRK2 and GBA1 mutations

Abstract

Keywords

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Cite this